Pfizer COVID-19 vaccine sales to reach $15B

Pfizer, the drug manufacturer with one of just a few approved Covid-19 vaccines on the market, is set to pull in more than $15 billion in revenue in 2021 from its entrant, according to S&P Global.

For perspective, that’s about as much as the drug giant’s top three best-selling pharmaceutical products. In total, Pfizer will deliver roughly 2 billion doses of its vaccine, which is administered in two doses to be completely effective, in 2021. By the end of May, more than 200 million doses are projected to have been delivered.

Currently, there are three FDA-approved COVID-19 vaccines in the U.S. market, including versions by Pfier-BioNTech, Moderna and Johnson & Johnson. All told, the U.S. has administered more than 127 million vaccine doses as of March 22, according to the Centers for Disease Control and Prevention.

While Pfizer is already well on its way to delivering hundreds of millions of doses, revenue from the shot is somewhat tricky to predict, Pfizer executives said during the company’s recent quarterly earnings call, as reported by S&P Global. However, revenue estimates rose after emerging issues with AstraZeneca, which has been administering an approved vaccine in Europe but faced challenges. Further, Pfizer’s competitor, Johnson & Johnson’s vaccine is not proven to be as effective as Pfizer’s and Moderna’s vaccine options.

While Pfizer puts the revenue for its COVID-19 vaccine in the $15 billion range, some analysts think it will be higher. Overall, the company’s 2021 revenue is anticipated to top $60 billion.

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”